Glaucoma QOL questionnaire ticks the right boxes

Article

The glaucoma-specific health-related quality of life questionnaire, Glau-Qol, demonstrates good correlations with disease progression in patients with glaucoma and ocular hypertension.

The glaucoma-specific health-related quality of life questionnaire, Glau-Qol, demonstrates good correlations with disease progression in patients with glaucoma and ocular hypertension (OHT), according to the results of a study published online ahead of print by Acta Ophthalmologica Scandinavica.

Alain Béchetoille from Paris and colleagues from across France enrolled patients with OHT or glaucoma (n=573) to take part in a cross-sectional psychometric validation study and a separate reproducibility study (n=244). Each subject answered the 36-item Glau-Qol questionnaire, which was designed from in-depth patient interviews.

The clinical validity of the questionnaire was found to be excellent. It clearly demonstrated that as disease severity and visual field impairment increased, health-related quality of life (HRQoL) scores from psychological wellbeing, self-image, daily life, driving, anxiety and burden of treatment domains were negatively affected. Increased age and lower visual acuity were also associated with lower HRQoL scores but to a lesser extent.

Psychometric validation demonstrated acceptable convergent and discriminant validity of the Glau-QoL and good reproducibility, with intra-class correlation coefficients and concordance correlation coefficients ≥0.69.

It was the conclusion of the researchers that the Glau-QoL questionnaire is a valid instrument that demonstrates excellent correlations with disease progression in patients with glaucoma and OHT.

Recent Videos
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Vikas Chopra at AAO 2024: Advancements in MIGS are transforming patient care
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
© 2024 MJH Life Sciences

All rights reserved.